EWTX - NASDAQ
Edgewise Therapeutics, Inc.
$36.21
-1.7%Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
At a Glance
Live SnapshotEdgewise Therapeutics, Inc. Management Team
Dr. Robert Blaustein M.D., Ph.D.
Chief Development Officer
Mr. R. Michael Carruthers
Chief Financial Officer
Compensation
$386,009
Dr. Joanne M. Donovan M.D., Ph.D.
Chief Medical Officer
Compensation
$824,817
Dr. Behrad Derakhshan Ph.D.
Chief Operating Officer
Compensation
$796,536
Dr. Alan J. Russell Ph.D.
Co-Founder, Chief Scientific Officer & Director
Compensation
$657,520
Mr. John R. Moore J.D.
General Counsel
Dr. Kevin Koch Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,074,828
Edgewise Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $199K and sold $6.54M worth of EWTX shares, resulting in $6.34M of net selling activity.
3 Months
0
0.00
114.9K
4.00M
-4.0M
-$4.00M
3-6 Months
0
0.00
13.7K
403.03K
-403K
-$403K
6-9 Months
10.7K
199.40K
100.0K
2.11M
-1.9M
-$1.91M
9-12 Months
0
0.00
100.0K
18.00K
-18K
-$18K
Top Buyers
Fox Jonathan C
Director
$199K
Top Sellers
Donovan Joanne M.
Officer: Cmo
$4.00M
Russell Alan J
Director, Officer: Chief Scientific Officer
$2.13M
Edris Badreddin
Director
$403K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $6.34M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
EWTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 13, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 23, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.